US3452014A - 2,5-dimethylpyrazine p-toluenesulfonate - Google Patents
2,5-dimethylpyrazine p-toluenesulfonate Download PDFInfo
- Publication number
- US3452014A US3452014A US444432A US3452014DA US3452014A US 3452014 A US3452014 A US 3452014A US 444432 A US444432 A US 444432A US 3452014D A US3452014D A US 3452014DA US 3452014 A US3452014 A US 3452014A
- Authority
- US
- United States
- Prior art keywords
- oil
- dimethylpyrazine
- acid
- methyl
- prepared
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- MQGBKWWRPALWQN-UHFFFAOYSA-N C1(=CC=C(C=C1)S(=O)(=O)O)C.CC1=NC=C(N=C1)C Chemical compound C1(=CC=C(C=C1)S(=O)(=O)O)C.CC1=NC=C(N=C1)C MQGBKWWRPALWQN-UHFFFAOYSA-N 0.000 title description 2
- LCZUOKDVTBMCMX-UHFFFAOYSA-N 2,5-Dimethylpyrazine Chemical group CC1=CN=C(C)C=N1 LCZUOKDVTBMCMX-UHFFFAOYSA-N 0.000 description 22
- 239000000203 mixture Substances 0.000 description 21
- 150000003839 salts Chemical class 0.000 description 15
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 14
- 239000000243 solution Substances 0.000 description 13
- -1 2,5 disubstituted pyrazine Chemical class 0.000 description 11
- 239000001934 2,5-dimethylpyrazine Substances 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 229910052751 metal Inorganic materials 0.000 description 8
- 239000002184 metal Substances 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 239000002480 mineral oil Substances 0.000 description 7
- 235000010446 mineral oil Nutrition 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000007903 gelatin capsule Substances 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 239000011149 active material Substances 0.000 description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000008157 edible vegetable oil Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 150000003216 pyrazines Chemical class 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000003549 soybean oil Substances 0.000 description 4
- 235000012424 soybean oil Nutrition 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 description 4
- 239000008158 vegetable oil Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 235000005687 corn oil Nutrition 0.000 description 3
- 239000002285 corn oil Substances 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000002329 infrared spectrum Methods 0.000 description 3
- 239000000944 linseed oil Substances 0.000 description 3
- 235000021388 linseed oil Nutrition 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 229920001800 Shellac Polymers 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 229940030486 androgens Drugs 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000007891 compressed tablet Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 229940030606 diuretics Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000012055 enteric layer Substances 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- DKEZXLQHHZBQAV-UHFFFAOYSA-N ethyl 5-methylpyrazine-2-carboxylate Chemical compound CCOC(=O)C1=CN=C(C)C=N1 DKEZXLQHHZBQAV-UHFFFAOYSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 239000008024 pharmaceutical diluent Substances 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000004208 shellac Substances 0.000 description 2
- 229940113147 shellac Drugs 0.000 description 2
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 2
- 235000013874 shellac Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 229960005371 tolbutamide Drugs 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 235000012431 wafers Nutrition 0.000 description 2
- VNDYJBBGRKZCSX-UHFFFAOYSA-L zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- ONDPHDOFVYQSGI-UHFFFAOYSA-N zinc nitrate Chemical compound [Zn+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ONDPHDOFVYQSGI-UHFFFAOYSA-N 0.000 description 2
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- QHCUFBJTNREJPR-LBPRGKRZSA-N (2s)-2-amino-3-[4-(4-hydroxyphenoxy)-3,5,5-triiodocyclohexa-1,3-dien-1-yl]propanoic acid Chemical compound IC1(I)CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C=C1 QHCUFBJTNREJPR-LBPRGKRZSA-N 0.000 description 1
- RJZQYQPFNYRNGM-IWPZMOPJSA-N (5R,8S,9S,10S,13S,14S)-7,10,13-trimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene Chemical class CC1[C@@H]2[C@H](CC[C@@]3(CCC[C@H]32)C)[C@]3(CCCC[C@@H]3C1)C RJZQYQPFNYRNGM-IWPZMOPJSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- VHRSUDSXCMQTMA-UHFFFAOYSA-N 11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-one Chemical compound CC12C=CC(=O)C=C1C(C)CC1C2C(O)CC2(C)C(O)(C(=O)CO)CCC21 VHRSUDSXCMQTMA-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- OFJWFSNDPCAWDK-UHFFFAOYSA-N 2-phenylbutyric acid Chemical compound CCC(C(O)=O)C1=CC=CC=C1 OFJWFSNDPCAWDK-UHFFFAOYSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- WSMQKESQZFQMFW-UHFFFAOYSA-N 5-methyl-pyrazole-3-carboxylic acid Chemical compound CC1=CC(C(O)=O)=NN1 WSMQKESQZFQMFW-UHFFFAOYSA-N 0.000 description 1
- OYBQCUZBVHFPBU-UHFFFAOYSA-N 5-methylpyrazine-2-carboxamide Chemical compound CC1=CN=C(C(N)=O)C=N1 OYBQCUZBVHFPBU-UHFFFAOYSA-N 0.000 description 1
- QMNAQPMXDMLOLD-UHFFFAOYSA-N 6-methyl-4-oxo-5,6-dihydrothieno[2,3-b]thiopyran-2-sulfonamide Chemical compound S1C(C)CC(=O)C2=C1SC(S(N)(=O)=O)=C2 QMNAQPMXDMLOLD-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- WDPFQABQVGJEBZ-MAKOZQESSA-N Bothermon Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1.O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 WDPFQABQVGJEBZ-MAKOZQESSA-N 0.000 description 1
- 241000273930 Brevoortia tyrannus Species 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- 244000007645 Citrus mitis Species 0.000 description 1
- RTPLCYNAEQZNQR-UHFFFAOYSA-N Cl.CC1=NC=C(N=C1)C Chemical compound Cl.CC1=NC=C(N=C1)C RTPLCYNAEQZNQR-UHFFFAOYSA-N 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- JYGLAHSAISAEAL-UHFFFAOYSA-N Diphenadione Chemical compound O=C1C2=CC=CC=C2C(=O)C1C(=O)C(C=1C=CC=CC=1)C1=CC=CC=C1 JYGLAHSAISAEAL-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- TZRXHJWUDPFEEY-UHFFFAOYSA-N Pentaerythritol Tetranitrate Chemical compound [O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O TZRXHJWUDPFEEY-UHFFFAOYSA-N 0.000 description 1
- 239000000026 Pentaerythritol tetranitrate Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 241001125046 Sardina pilchardus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 229940124332 anorexigenic agent Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- HUTDDBSSHVOYJR-UHFFFAOYSA-H bis[(2-oxo-1,3,2$l^{5},4$l^{2}-dioxaphosphaplumbetan-2-yl)oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O HUTDDBSSHVOYJR-UHFFFAOYSA-H 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- DXXUGBPKQDTBQW-UHFFFAOYSA-L chlorisondamine Chemical compound [Cl-].[Cl-].ClC1=C(Cl)C(Cl)=C(Cl)C2=C1C[N+](CC[N+](C)(C)C)(C)C2 DXXUGBPKQDTBQW-UHFFFAOYSA-L 0.000 description 1
- 229950002565 chlorisondamine Drugs 0.000 description 1
- 229960001761 chlorpropamide Drugs 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- OUZWUKMCLIBBOG-UHFFFAOYSA-N ethoxzolamide Chemical compound CCOC1=CC=C2N=C(S(N)(=O)=O)SC2=C1 OUZWUKMCLIBBOG-UHFFFAOYSA-N 0.000 description 1
- 229950005098 ethoxzolamide Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000004140 ketosis Effects 0.000 description 1
- YDTFRJLNMPSCFM-YDALLXLXSA-M levothyroxine sodium anhydrous Chemical compound [Na+].IC1=CC(C[C@H](N)C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 YDTFRJLNMPSCFM-YDALLXLXSA-M 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940040504 lipotropic agent Drugs 0.000 description 1
- 239000003912 lipotropic agent Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004533 oil dispersion Substances 0.000 description 1
- 229940100692 oral suspension Drugs 0.000 description 1
- 239000001048 orange dye Substances 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- XEEVLJKYYUVTRC-UHFFFAOYSA-N oxomalonic acid Chemical compound OC(=O)C(=O)C(O)=O XEEVLJKYYUVTRC-UHFFFAOYSA-N 0.000 description 1
- 229960004321 pentaerithrityl tetranitrate Drugs 0.000 description 1
- 229960001753 phenformin hydrochloride Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- NIPZZXUFJPQHNH-UHFFFAOYSA-N pyrazine-2-carboxylic acid Chemical class OC(=O)C1=CN=CC=N1 NIPZZXUFJPQHNH-UHFFFAOYSA-N 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000019512 sardine Nutrition 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- YDTFRJLNMPSCFM-UTONKHPSSA-M sodium;(2r)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoate Chemical compound [Na+].IC1=CC(C[C@@H](N)C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 YDTFRJLNMPSCFM-UTONKHPSSA-M 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 239000004246 zinc acetate Substances 0.000 description 1
- 229940102001 zinc bromide Drugs 0.000 description 1
- 239000011667 zinc carbonate Substances 0.000 description 1
- 235000004416 zinc carbonate Nutrition 0.000 description 1
- 229910000010 zinc carbonate Inorganic materials 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 229960001939 zinc chloride Drugs 0.000 description 1
- LRXTYHSAJDENHV-UHFFFAOYSA-H zinc phosphate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O LRXTYHSAJDENHV-UHFFFAOYSA-H 0.000 description 1
- 229910000165 zinc phosphate Inorganic materials 0.000 description 1
- 229940077935 zinc phosphate Drugs 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Definitions
- R is alkyl and R is selected from the group consisting of alkyl, carboxyl, alkoxycarbonyl, carbamoyl and monoand dialkyl substituted carbamoyl, said alkyl groups containing 1 through 4 carbon atoms, and physiologically acceptable salts thereof.
- novel compounds and primary active ingredients utilized in the novel compositions and method of this invention are represented by the formula wherein R is alkyl and R is alkyl, carboxyl, alkoxycarbonyl, carbamoyl and monoand dialkyl-substituted carbamoyl, the alkyl groups containing 1 through 4 carbon atoms, and physiologically acceptable salts of the foregoing compounds.
- salts acid addition salts, such as the hydrochloride, cyclohexylsulfamate, sulfate, acetate, nitrate, phosphate, citrate, maleate, tartrate, succinate, pamoate, p-toluenesulfonate, benzenesulfonate and the like of the foregoing pyrazines; alkali metal salts (such as sodium and potassium), alkaline earth metal salts (such as aluminum, calcium and magnesium), amine salts (such as N,N-dibenzylethylenediamine, procaine and diethanolamine), and ammonium salts of the carboxypyrazines; and metal salt complexes of the formula wherein R and R are as above defined, nis an integer less than 3, and MS is a physiologically acceptable metal salt, such as the chlorides, bromides, phosphates, sulfates, nitrates, acetates and carbonates of Zinc, iron,
- the compounds of this invention are prepared by methods well known in the art, e.g., by the methods and obvious adaptations thereof described at J. Prakt. chim. (2) 47:455, 480 (1893) Chem. Abs. 42: P5055i (1948).
- the exact schedule of adminstration in animals is determined individually according to the subjects age, Weight, response to the medication and nature and severity of the condition being treated.
- pyrazines in addition to 2,5-disubstituted pyrazines as the sole active ingredient, other complementary ingredients can be included in the composition to secure advantageous combinations of properties especially adapted to individual situations in the treatment of the foregoing conditions.
- hypoglycemic agents such as tolbutamide, N- (hexahydro 1 azepinyl carbamoyl)-p-toluenesulfonamide, chloropropamide, phenformin hydrochloride, 5- methylpyrazole-3-carboxylic acid, mesoxalic acid, insulin, nicotinic acid, and the like can be included in the present formulations in amounts not exceeding and preferably less than those normally employed in single unit doses where such added ingredients are employed alone.
- Utilizable potassium salts such as potassium chloride, can be included to offset possible potassium losses during therapy.
- Such combinations include also conventional therapeutic amounts or less of other hypocholesteremic agents such as the D-isomer of 3,5,3-triiodothyronine, triiodothyropropionic acid, and thyroxine-like compounds such as sodium L-thyroxine and sodium D-thyroxine; glucocorticoids such as hydrocortisone, prednisolone and 6a-methylprednisolone; anticoagulants such as heparin, 2-diphenylacetyl-1,3-indandione, polyethylene sulfonate and dimmarol or its derivatives; unsaturated fatty acids such as linoleic acid, linolenic acid and arachidonic acid or edible oils containing these unsaturated fatty acids such as purified linseed oil, soybean oil, safflower oil, corn oil, sardine oil, menhaden oil, and the like; vitamins such as nicotinic acid, vitamin B ascor
- novel compositions are suitably presented for administration in unit dosage form as tablets, pills, capsules, powders, wafers, cachets, granules, oral or parenteral fluid preparations, including elixirs, aqueous and oil dispersions and the like.
- the active ingredient is mixed with a conventional non-sugar tableting component such as cornstarch, dicalcium phosphate, terra alba (calcium sulfate), talc, stearic acid, calcium stearate, gums, and functionally similar materials constituting pharmaceutical diluents, granulating agents or carriers.
- a conventional non-sugar tableting component such as cornstarch, dicalcium phosphate, terra alba (calcium sulfate), talc, stearic acid, calcium stearate, gums, and functionally similar materials constituting pharmaceutical diluents, granulating agents or carriers.
- the tablets or pills can be laminated or otherwise compounded to provide a dosage form affording the advantage of prolonged or delayed action or of predetermined successive action of the enclosed medication.
- the tablet or pill can comprise an inner dosage and outer dosage component, the latter being in the form of an envelope over the former.
- the two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release.
- enteric layers or coatings such materials including a number of polymeric acids or mixtures of polymeric acids with such materials as shellac, shellac and cetyl alcohol, cellulose acetate phthalate and the like.
- a particularly advantageous sustained release coating comprises a styrene maleic acid copolymer.
- the liquid form in which the novel compositions of this invention can be incorporated include oil disperions or emulsions, aqueous sugar-free solutions or suspensions, emulsions or suspensions with edible oils such as soybean oil, purified linseed oil, cottonseed oil, sesame oil, corn oil, safliower oil, and the like, as well as elixirs and similar pharmaceutical vehicles.
- Suitable dispersing or suspending agents for aqueous suspensions include the synthetic and natural gums such as tragacanth, acacia, alginate, dextran, methylcellulose, polyvinylpyrrolidone, gelatin and the like.
- compositions of 2,5-dimethyl-pyrazine the fact that this compound is a volatile liquid must be considered.
- Salts such as the hydrochloride, are solid but may be discolored on contact with metals.
- Appropriate oral liquid dosage forms include conventional sugar-free syrups, elixirs and solutions for use as drops or by the teaspoonful.
- Suitable non-aqueous vehicles for oral use include the edible oils (e.g., purified linseed oil, corn oil, cottonseed oil, soybean oil and other vegetable oils), mineral oil, glycerol, propylene glycol, polyethylene glycol 200-600, sorbitol, ethanol, or mixtures of these (e.g., equal parts of soybean oil and propylene glycol).
- Aqueous vehicles are also suitable.
- Liquid preparations for intramuscular or subcutaneous injection can be prepared as ethanolic-aqueous, propylene glycol-aqueous or oil solutions (e.g., vegetable oils such as peanut oil) and in repository-type vehicles such as aluminum monostearate-peanut oil gel. In general, liquid formulations range in concentration from about 05-50% 2,5-dimethylpyrazine.
- the solid dosage forms of 2,5-dimethylpyrazine require the intermediate preparation of the liquid active ingredient as discrete solid particles which can be employed to build the ultimate dosage form by conventional methods.
- the 2,5-dimethylpyrazine can be dissolved or dispersed in an edible oil such as a vegetable or mineral oil (in ratios of, for example, about 1:1 to 1:200) and soft elastic capsules containing the oil dispersion or solution prepared for oral use.
- Triturates of 2,5-dimethylpyrazine can be made using various absorbing powders such as kaolin, magnesium carbonate, bentonite, magnesium oxide, starch, calcium carbonate, tribasic calcium phosphate, magnesium trisilicate and the like.
- Solid metal salt complexes of the liquid 2,5-dirnethylpyrazine or other 2,5-disubstituted pyrazines can also be prepared for conventional formulation.
- metal salt complexes of the 2,5-substituted pyrazines as described herein those formed with zinc salts, such as zinc chloride, zinc bromide, zinc phosphate, zinc sulfate, zinc nitrate, zinc acetate, zinc carbonate and the like, are preferred.
- zinc salts such as zinc chloride, zinc bromide, zinc phosphate, zinc sulfate, zinc nitrate, zinc acetate, zinc carbonate and the like.
- conventional procedures are employed to give complexes having either 1:1 or 2:1 ratios of pyrazine to metal salt.
- the 221 complex is preferred because it provides a higher proportion of active material per unit weight.
- Bringing together the desired metal salt and substituted pyrazine in a common solvent, with stirring, is sufiicient to produce the desired complex in high yield.
- a molar excess of substituted pyrazine will give a 2:1 ratio of pyrazine to metal salt, less than a molar excess giving the 1:1
- unit dosage form refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required pharmaceutical diluent, carrier or vehicle.
- the specification for the novel unit dosage forms of this invention are dictated by and directly dependent on (a) the unique characteristics of the active material and the particular therapeutic effect to be achieved and (b) the limitations inherent in the art of compounding such an active material for therapeutic use as disclosed in detail in this specification, these being features of the present invention.
- suitable unit dosage forms are tablets, capsules, pills, powder packets, wafers, cachets, granules, solutions or suspensions for oral or sterile injectable use, suppositories, and segregated multiples of any of the foregoing, and other forms alluded to herein.
- Example 1 Soft gelatin capsules A batch of 1,000 soft gelatin capsules, each containing mg. of 2,5-dimethylpyrazine in mineral oil, is prepared from the following materials:
- One capsule is given twice a day in the treatment of hyperlipidemia.
- Example 2 Compressed tablets A lot of 10,000 compressed tablets, each containing 100 mg. of Z-methyl-S-carboxypyrazine, is prepared from the following ingredients:
- the Z-methyl-S-carboxypyrazine and terra alba are mixed well, granulated with 7.5% solution of methylcellulose in water, passed through a No. 8 screen and dried at F.
- the dried granules are passed through a No. 12 screen, mixed thoroughly with the tale and stearate and compressed into tablets.
- Example 3Injectable preparation An injectable preparation is made from the following ingredients to contain 500 mg. of 2-methyl-5-ethoxycarbonylpyrazine per ml.
- the previously sterilized active ingredient is homogenized with the already mixed and sterilized vehicle.
- the novel 2-methyl-5-ethoxycarbonylpyrazine can be prepared by adding ml. of thionyl chloride to 13.8 gm. (0.1 mole) of Z-methyl-5-carboxypyrazine (Beil. [4], 25, 126) in 200 ml. of dry benzene. The mixture is heated under reflux for two hours and the benzene and excess thionyl chloride removed by distillation under vacuum. The residue is added to 25 ml. of anhydrous ethanol and the mixture heated under reflux for one hour. The excess ethanol is removed by distillation under vacuum and the residue purified by recrystallization to give substantially pure Z-methyl-5-ethoxycarbonylpyrazine.
- lower alkyl esters are prepared by substituting the appropriate alkanol for the ethanol in the above reaction.
- Acid addition salts are prepared by contacting the free base with the appropriate acid in the usual manner.
- Example 4 An aqueous oral suspension containing, in each 5 ml., 200 mg. of 2-methyl-S-carbamoylpyrazine (Chem. Abstr. 42zP5055i [1948]) is prepared from the following materials:
- Example 5 A lot of 10,000 two-piece hard gelatin capsules for oral use, each containing 100 mg. of N,N-dimethyl-2- methyl-S-carbamoylpyrazine, is prepared from the following materials:
- N-methyl-Z-methyl-S-carbamoylpyrazine is prepared by substituting a solution of excess methylamine in benzene in place of the dimethylamine above.
- N,N-dialkyland N-alkyl-Z-methyl-S-carbamoylpyrazines are prepared as above by substituting the appropriate dialkylor monoalkyl amine for the dimethylamine.
- 2,5-dimethylpyrazine hydrochloride To a cold solution of 54 ml. (0.5 mole) of 2,5-dimethylpyrazine in 5 00 ml. of anhydrous ether was added 200 ml. of a 2.8N ethereal-hydrochloride solution. The hydrochloride solution was added over a 20-minute period keeping the reaction temperature at 10-15 C. The mixture was stirred for /2 hr., then filtered and washed with ether to give 66.4 gm. (92%) of product which melted at l58l59 C. After three recrystallizations from isopropanol there was obtained 36 gm. (50%) of product which melts at l65.5 C. (turns greenish-black on melting).
- 2,5-dimethylpyrazine nitrate.T0 a cold solution of 15 ml. (0.15 mole) of 2,5-dimethylpyrazine in 15 ml. of isopropanol was slowly added 10 ml. (0.158 mole) of concentrated nitric acid. The mixture was stirred in an ice bath for 15 minutes and 16 ml. of anhydrous ether was added. The reaction mixture was filtered and washed with cold isopropanol and ether to give 13 gm. (50%) of the purple product which melted at 83-85 C. This material was recrystallized from isopropanol to give 9 gm. (35%) of the product in long purple needles which melt at 84-85 C.
- 2,5-dimethylpyrazine p-toluenesulfonate To a solution of 10 gm. (0.058 mole) of p-toluenesulfonic acid in 20 ml. of isopropanol was added 5 ml. (0.05 mole) of 2,5-dimethylpyrazine. The solution was stirred for a few minutes and then seeded at which point it solidified. The reaction mixture was filtered and washed with isopropanol and ether. The product was recrystallized two times from isopropanol to give 7 gm. (50%) of product which melts at 144.5146 C. The product was colorless and is not volatile.
- This novel salt is distinguished by unusual suitability for pharmaceutical formulation, particularly in terms of such properties as non-volatility and stability.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
United States Patent Q US. Cl. 260250 1 Claim ABSTRACT OF THE DISCLOSURE Therapeutic composition and method for treating hyperlipidemia in mammals involving a 2,5 disubstituted pyrazine of the formula:
RI IT wherein R is alkyl and R is selected from the group consisting of alkyl, carboxyl, alkoxycarbonyl, carbamoyl and monoand dialkyl substituted carbamoyl, said alkyl groups containing 1 through 4 carbon atoms, and physiologically acceptable salts thereof.
This application is a continuation-in-part of application Ser. No. 389,791, filed Aug. 14, 1964, now abandoned.
The novel compounds and primary active ingredients utilized in the novel compositions and method of this invention are represented by the formula wherein R is alkyl and R is alkyl, carboxyl, alkoxycarbonyl, carbamoyl and monoand dialkyl-substituted carbamoyl, the alkyl groups containing 1 through 4 carbon atoms, and physiologically acceptable salts of the foregoing compounds. By salts is meant acid addition salts, such as the hydrochloride, cyclohexylsulfamate, sulfate, acetate, nitrate, phosphate, citrate, maleate, tartrate, succinate, pamoate, p-toluenesulfonate, benzenesulfonate and the like of the foregoing pyrazines; alkali metal salts (such as sodium and potassium), alkaline earth metal salts (such as aluminum, calcium and magnesium), amine salts (such as N,N-dibenzylethylenediamine, procaine and diethanolamine), and ammonium salts of the carboxypyrazines; and metal salt complexes of the formula wherein R and R are as above defined, nis an integer less than 3, and MS is a physiologically acceptable metal salt, such as the chlorides, bromides, phosphates, sulfates, nitrates, acetates and carbonates of Zinc, iron, aluminum, magnesium and calcium and the like.
The compounds of this invention are prepared by methods well known in the art, e.g., by the methods and obvious adaptations thereof described at J. Prakt. chim. (2) 47:455, 480 (1893) Chem. Abs. 42: P5055i (1948).
These compounds have been unexpectedly found to exhibit several times the oral hypoglycemic activity of tolbutamide in standard test animals. This pronounced activity is accompanied by a low order of toxicity, making pharmaceutical compositions containing such compounds useful in reducing the blood sugar content of mammals, and in particular for administration by the preferred oral route. These compounds as formulated herein are also useful in treating ketosis, as anti-inflammatory agents in the management of inflammatory conditions for which steroids are normally employed, and as diuretics.
It has also been discovered that representative compounds of the group here disclosed are effective in reducing the free fatty acids, cholesterol and triglycerides content of blood in mammals. These activities, demonstrated at acceptable therapeutic ratios, make the compounds herein useful as compositions in treating such conditions as atherosclerosis, arteriosclerosis, blood-clotting defects due to lipermia, and other clinical entities in which the underlying etiology is associated with lipid imbalance or hyperlipidemia.
In utilizing the compositions and practicing the method of this invention, the exact schedule of adminstration in animals is determined individually according to the subjects age, Weight, response to the medication and nature and severity of the condition being treated.
In addition to 2,5-disubstituted pyrazines as the sole active ingredient, other complementary ingredients can be included in the composition to secure advantageous combinations of properties especially adapted to individual situations in the treatment of the foregoing conditions. Thus, other hypoglycemic agents such as tolbutamide, N- (hexahydro 1 azepinyl carbamoyl)-p-toluenesulfonamide, chloropropamide, phenformin hydrochloride, 5- methylpyrazole-3-carboxylic acid, mesoxalic acid, insulin, nicotinic acid, and the like can be included in the present formulations in amounts not exceeding and preferably less than those normally employed in single unit doses where such added ingredients are employed alone. Utilizable potassium salts, such as potassium chloride, can be included to offset possible potassium losses during therapy.
Such combinations include also conventional therapeutic amounts or less of other hypocholesteremic agents such as the D-isomer of 3,5,3-triiodothyronine, triiodothyropropionic acid, and thyroxine-like compounds such as sodium L-thyroxine and sodium D-thyroxine; glucocorticoids such as hydrocortisone, prednisolone and 6a-methylprednisolone; anticoagulants such as heparin, 2-diphenylacetyl-1,3-indandione, polyethylene sulfonate and dimmarol or its derivatives; unsaturated fatty acids such as linoleic acid, linolenic acid and arachidonic acid or edible oils containing these unsaturated fatty acids such as purified linseed oil, soybean oil, safflower oil, corn oil, sardine oil, menhaden oil, and the like; vitamins such as nicotinic acid, vitamin B ascorbic acid and pyridoxine hydrochloride, estrogens such as estradiol; androgens such as testosterone and 7-methylandrostanes such as or 7B- methyl-5a-androstane-3fl,17,8-diol; combinations of estrogens and androgens such as estradiol and testosterone; antibiotics such as neomycin; analgesics such as aspirin; compounds associated with cholesterol synthesis or metabolism such as a-phenylbutyric acid, ethyl chlorophenoxyisobutyrate and a-p-biphenylylbutyric acid; lipotropic agents such as choline and inositol; amino acids such as taurine and glycine; sterols such as sitosterol and other plant sterols; diuretics such as ethoxzolamide and hydrochlorothiazide; anorexigenic agents such as amphetamine; cardiovascular agents (including vasodilators and hypotensive agents), such as chlorisondamine chloride, hexamethonium chloride, and pentaerythritol tetranitrate.
In adapting the active ingredients for use in mammals the novel compositions are suitably presented for administration in unit dosage form as tablets, pills, capsules, powders, wafers, cachets, granules, oral or parenteral fluid preparations, including elixirs, aqueous and oil dispersions and the like.
For preparing solid compositions such as tablets, the active ingredient is mixed with a conventional non-sugar tableting component such as cornstarch, dicalcium phosphate, terra alba (calcium sulfate), talc, stearic acid, calcium stearate, gums, and functionally similar materials constituting pharmaceutical diluents, granulating agents or carriers. The tablets or pills can be laminated or otherwise compounded to provide a dosage form affording the advantage of prolonged or delayed action or of predetermined successive action of the enclosed medication. For example, the tablet or pill can comprise an inner dosage and outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids or mixtures of polymeric acids with such materials as shellac, shellac and cetyl alcohol, cellulose acetate phthalate and the like. A particularly advantageous sustained release coating comprises a styrene maleic acid copolymer.
The liquid form in which the novel compositions of this invention can be incorporated include oil disperions or emulsions, aqueous sugar-free solutions or suspensions, emulsions or suspensions with edible oils such as soybean oil, purified linseed oil, cottonseed oil, sesame oil, corn oil, safliower oil, and the like, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions include the synthetic and natural gums such as tragacanth, acacia, alginate, dextran, methylcellulose, polyvinylpyrrolidone, gelatin and the like.
In preparing pharmaceutical compositions of 2,5-dimethyl-pyrazine, the fact that this compound is a volatile liquid must be considered. (Salts, such as the hydrochloride, are solid but may be discolored on contact with metals.) Appropriate oral liquid dosage forms include conventional sugar-free syrups, elixirs and solutions for use as drops or by the teaspoonful. Suitable non-aqueous vehicles for oral use include the edible oils (e.g., purified linseed oil, corn oil, cottonseed oil, soybean oil and other vegetable oils), mineral oil, glycerol, propylene glycol, polyethylene glycol 200-600, sorbitol, ethanol, or mixtures of these (e.g., equal parts of soybean oil and propylene glycol). Aqueous vehicles are also suitable. Liquid preparations for intramuscular or subcutaneous injection can be prepared as ethanolic-aqueous, propylene glycol-aqueous or oil solutions (e.g., vegetable oils such as peanut oil) and in repository-type vehicles such as aluminum monostearate-peanut oil gel. In general, liquid formulations range in concentration from about 05-50% 2,5-dimethylpyrazine.
The solid dosage forms of 2,5-dimethylpyrazine require the intermediate preparation of the liquid active ingredient as discrete solid particles which can be employed to build the ultimate dosage form by conventional methods. Alternatively, the 2,5-dimethylpyrazine can be dissolved or dispersed in an edible oil such as a vegetable or mineral oil (in ratios of, for example, about 1:1 to 1:200) and soft elastic capsules containing the oil dispersion or solution prepared for oral use. Triturates of 2,5-dimethylpyrazine can be made using various absorbing powders such as kaolin, magnesium carbonate, bentonite, magnesium oxide, starch, calcium carbonate, tribasic calcium phosphate, magnesium trisilicate and the like. Emulsifying the liquid 2,5-dimethylpyrazine, preferably dissolved in a suitable vegetable oil or mineral oil, to provide small particle sizes and then coating the said particles with a coacervate of one or more hydrophilic colloids, pharmaceutically acceptable copolymers, or mixtures thereof yields, on drying, free-flowing granulations which can be handled essentially as solid particles and formulated as powders, granules, tablets, hard-filled capsules and the like. Solid metal salt complexes of the liquid 2,5-dirnethylpyrazine or other 2,5-disubstituted pyrazines can also be prepared for conventional formulation.
Among the metal salt complexes of the 2,5-substituted pyrazines as described herein, those formed with zinc salts, such as zinc chloride, zinc bromide, zinc phosphate, zinc sulfate, zinc nitrate, zinc acetate, zinc carbonate and the like, are preferred. In preparing these complexes, conventional procedures are employed to give complexes having either 1:1 or 2:1 ratios of pyrazine to metal salt. The 221 complex is preferred because it provides a higher proportion of active material per unit weight. Bringing together the desired metal salt and substituted pyrazine in a common solvent, with stirring, is sufiicient to produce the desired complex in high yield. A molar excess of substituted pyrazine will give a 2:1 ratio of pyrazine to metal salt, less than a molar excess giving the 1:1 complex.
The term unit dosage form as used in the specification and claims herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required pharmaceutical diluent, carrier or vehicle. The specification for the novel unit dosage forms of this invention are dictated by and directly dependent on (a) the unique characteristics of the active material and the particular therapeutic effect to be achieved and (b) the limitations inherent in the art of compounding such an active material for therapeutic use as disclosed in detail in this specification, these being features of the present invention. Examples of suitable unit dosage forms, as heretofore described, are tablets, capsules, pills, powder packets, wafers, cachets, granules, solutions or suspensions for oral or sterile injectable use, suppositories, and segregated multiples of any of the foregoing, and other forms alluded to herein.
The following examples illustrate the best mode contemplated by the inventor for carrying out the invention but are not to be construed as limiting the scope thereof.
Example 1.Soft gelatin capsules A batch of 1,000 soft gelatin capsules, each containing mg. of 2,5-dimethylpyrazine in mineral oil, is prepared from the following materials:
\Grams 2,5-dimethylpyrazine 100 Mineral oil, USP 100 A uniform dispersion of the active ingredient in the mineral oil is prepared and the dispersion filled into soft gelatin capsules by conventional means.
One capsule is given twice a day in the treatment of hyperlipidemia.
Example 2.--Compressed tablets A lot of 10,000 compressed tablets, each containing 100 mg. of Z-methyl-S-carboxypyrazine, is prepared from the following ingredients:
The Z-methyl-S-carboxypyrazine and terra alba are mixed well, granulated with 7.5% solution of methylcellulose in water, passed through a No. 8 screen and dried at F. The dried granules are passed through a No. 12 screen, mixed thoroughly with the tale and stearate and compressed into tablets.
Example 3.Injectable preparation An injectable preparation is made from the following ingredients to contain 500 mg. of 2-methyl-5-ethoxycarbonylpyrazine per ml.
The previously sterilized active ingredient is homogenized with the already mixed and sterilized vehicle.
Six thousand units of insulin can be added to the above formulation to give a combination product administrable in 0.5 ml. amounts or less daily.
The novel 2-methyl-5-ethoxycarbonylpyrazine can be prepared by adding ml. of thionyl chloride to 13.8 gm. (0.1 mole) of Z-methyl-5-carboxypyrazine (Beil. [4], 25, 126) in 200 ml. of dry benzene. The mixture is heated under reflux for two hours and the benzene and excess thionyl chloride removed by distillation under vacuum. The residue is added to 25 ml. of anhydrous ethanol and the mixture heated under reflux for one hour. The excess ethanol is removed by distillation under vacuum and the residue purified by recrystallization to give substantially pure Z-methyl-5-ethoxycarbonylpyrazine.
Other lower alkyl esters are prepared by substituting the appropriate alkanol for the ethanol in the above reaction. Acid addition salts are prepared by contacting the free base with the appropriate acid in the usual manner.
Example 4 An aqueous oral suspension containing, in each 5 ml., 200 mg. of 2-methyl-S-carbamoylpyrazine (Chem. Abstr. 42zP5055i [1948]) is prepared from the following materials:
2-methyl-5-carbamoylpyrazine gm 400.0 Methylparaben, USP gm 7.5 Propylparaben, USP gm 2.5 Saccharin sodium gm 12.5 Cyclamate sodium gm 2.5 Glycerin ml 3000.0 Tragacanth powder ..-gm 100.0 Orange oil flavor gm 10.0 F. D. and C. orange dye gm 7.5 Deionized water ml q.s-.. 10,0000
Example 5.--Hard gelatin capsules A lot of 10,000 two-piece hard gelatin capsules for oral use, each containing 100 mg. of N,N-dimethyl-2- methyl-S-carbamoylpyrazine, is prepared from the following materials:
fGrams N,N-dimethyl-2-methyl-S-carbamoylpyrazine 1000.0 Potassium chloride 1000.0 Mineral oil, USP 129.6 Magnesium stearate, powder 162.0 Talc, USP 162.0 Corn starch 1616.0
of dimethylamine is added dropwise with cooling in an ice bath. When addition is complete the mixture is stirred overnight at room temperature. The mixture is then filtered and the filtrate concentrated to dryness. The
crude product is purified by recrystallization from ethanolwater to give substantially pure N,N-dimethyl-2-methyl- -carbamoylpyrazine.
N-methyl-Z-methyl-S-carbamoylpyrazine is prepared by substituting a solution of excess methylamine in benzene in place of the dimethylamine above.
Other N,N-dialkyland N-alkyl-Z-methyl-S-carbamoylpyrazines are prepared as above by substituting the appropriate dialkylor monoalkyl amine for the dimethylamine.
The salts for incorporation in formulations such as above are illustratively represented as follows:
2,5-dimethylpyrazine hydrochloride.To a cold solution of 54 ml. (0.5 mole) of 2,5-dimethylpyrazine in 5 00 ml. of anhydrous ether was added 200 ml. of a 2.8N ethereal-hydrochloride solution. The hydrochloride solution was added over a 20-minute period keeping the reaction temperature at 10-15 C. The mixture was stirred for /2 hr., then filtered and washed with ether to give 66.4 gm. (92%) of product which melted at l58l59 C. After three recrystallizations from isopropanol there was obtained 36 gm. (50%) of product which melts at l65.5 C. (turns greenish-black on melting).
Analysis.Calcd. for C H N Cl: C, 49.83; H, 6.27; N, 19.38; Cl, 24.52. Found: C, 49.43; H, 6.24; N, 19.06; Cl, 24.48. Infrared and NMR spectra support the structure.
2,5-dimethylpyrazine nitrate.T0 a cold solution of 15 ml. (0.15 mole) of 2,5-dimethylpyrazine in 15 ml. of isopropanol was slowly added 10 ml. (0.158 mole) of concentrated nitric acid. The mixture was stirred in an ice bath for 15 minutes and 16 ml. of anhydrous ether was added. The reaction mixture was filtered and washed with cold isopropanol and ether to give 13 gm. (50%) of the purple product which melted at 83-85 C. This material was recrystallized from isopropanol to give 9 gm. (35%) of the product in long purple needles which melt at 84-85 C.
Analysis.-Calcd. for C H N O C. 42.10; H, 5.30; N, 24.55. Found: C, 41.73; H, 5.37; N, 24.40. Infrared spectrum supports the structure.
2,5-dimethylpyrazine p-toluenesulfonate.To a solution of 10 gm. (0.058 mole) of p-toluenesulfonic acid in 20 ml. of isopropanol was added 5 ml. (0.05 mole) of 2,5-dimethylpyrazine. The solution was stirred for a few minutes and then seeded at which point it solidified. The reaction mixture was filtered and washed with isopropanol and ether. The product was recrystallized two times from isopropanol to give 7 gm. (50%) of product which melts at 144.5146 C. The product was colorless and is not volatile.
Analysis.--Calcd. for C H N O S: C. 55.69; H, 5.75; N, 10.00; S, 11.44. Found: C, 55.95; H, 5.75; N, 9.91; S, 11.10. Infrared spectrum supports the structure.
This novel salt is distinguished by unusual suitability for pharmaceutical formulation, particularly in terms of such properties as non-volatility and stability.
Example 6 wherein R and R are hereinbefore defined, gives compositions useful as indicated.
Other complementary ingredients and combinations as illustratively disclosed are added in amounts not exceeding 7 8 those r 1orma1ly emplcyed for each dosage unit when such OTHER REFERENCES- 3 s= 4 Dalmer et' a1. (Merck) Chem. Abst. vol. 30, column at alme 6894 (1936) qdi.A51.
1. 2,5-dimethy1pyrazine p-toluenesulfonate.
5 HENRY R. JILES, Primary Examiner.
NATALIE TROUSOF, Assistant Examiner.
References Cited UNITED STATES PATENTS 3,067,199 12/ 1962 Langdon 260-250 USCLXR.
FOREIGN PATENTS 10 260242; 424--240, 243, 250
597,889 2/19'48 Great Britain.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38979164A | 1964-08-14 | 1964-08-14 | |
US44443265A | 1965-03-31 | 1965-03-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
US3452014A true US3452014A (en) | 1969-06-24 |
Family
ID=27012842
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US444432A Expired - Lifetime US3452014A (en) | 1964-08-14 | 1965-03-31 | 2,5-dimethylpyrazine p-toluenesulfonate |
Country Status (5)
Country | Link |
---|---|
US (1) | US3452014A (en) |
BE (1) | BE668306A (en) |
FR (1) | FR4615M (en) |
GB (1) | GB1113262A (en) |
IL (1) | IL23887A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2319834A1 (en) * | 1972-04-28 | 1973-11-15 | Erba Carlo Spa | PYRAZINE DERIVATIVES, THE PROCESS FOR THEIR MANUFACTURING AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM |
US4340594A (en) * | 1980-05-15 | 1982-07-20 | The Green Cross Corporation | Fat emulsion containing steroid |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB597889A (en) * | 1943-12-10 | 1948-02-05 | Merck & Co Inc | The manufacture of 2-amino-5-methyl pyrazine |
US3067199A (en) * | 1956-09-13 | 1962-12-04 | Wyandotte Chemicals Corp | Method for preparing alkyl-substituted piperazines, alkyl-substituted pyrazines, andmixtures thereof |
-
1965
- 1965-03-31 US US444432A patent/US3452014A/en not_active Expired - Lifetime
- 1965-06-18 GB GB25938/65A patent/GB1113262A/en not_active Expired
- 1965-07-05 IL IL23887A patent/IL23887A/en unknown
- 1965-08-13 FR FR28295A patent/FR4615M/fr not_active Expired
- 1965-08-13 BE BE668306A patent/BE668306A/xx unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB597889A (en) * | 1943-12-10 | 1948-02-05 | Merck & Co Inc | The manufacture of 2-amino-5-methyl pyrazine |
US3067199A (en) * | 1956-09-13 | 1962-12-04 | Wyandotte Chemicals Corp | Method for preparing alkyl-substituted piperazines, alkyl-substituted pyrazines, andmixtures thereof |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2319834A1 (en) * | 1972-04-28 | 1973-11-15 | Erba Carlo Spa | PYRAZINE DERIVATIVES, THE PROCESS FOR THEIR MANUFACTURING AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM |
US4340594A (en) * | 1980-05-15 | 1982-07-20 | The Green Cross Corporation | Fat emulsion containing steroid |
Also Published As
Publication number | Publication date |
---|---|
FR4615M (en) | 1966-11-21 |
GB1113262A (en) | 1968-05-08 |
IL23887A (en) | 1969-05-28 |
BE668306A (en) | 1966-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3924001A (en) | Hypolipidemic 4-(monoalkylamino)benzoic acid derivatives | |
US3029189A (en) | S-aryl-z-mno-x-qxazolibinones | |
US2838519A (en) | Process for the conversion of stereoisomers | |
US3634431A (en) | Acylated and alkylated derivatives of 2-aminohexahydrobenzo(a)quinolizines | |
US4517198A (en) | Diuretic imidazole derivatives | |
US3388128A (en) | Substituted 1, 4-diazabicyclo [4. 4. 9] decanes | |
US3277108A (en) | Certain aralkyl sydnonimines | |
US3452014A (en) | 2,5-dimethylpyrazine p-toluenesulfonate | |
US3755383A (en) | Sulfamyl-anthranilic acids | |
US3359269A (en) | 3-amino-5-substituted-pyrazinoyl-guanidines | |
US3139381A (en) | Process of effecting diuresis with nitro disulfamylaniline compounds | |
US3530126A (en) | N-heterocyclic substituted cyclohexanes | |
US3798262A (en) | Sulfonylbenzenesulfonic acids | |
US3674787A (en) | 2-(alpha-morpholinobenzyl)-anilides | |
CH651554A5 (en) | SULFURIZED ISOCHINOL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THE PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS. | |
US3060206A (en) | 2, 4-disulfamyl-5-alkoxy-aniline | |
US3072720A (en) | Novel n-arylsulfonyl-n'-(2, 5-endomethylene-1, 2, 5, 6-tetrahydrobenzyl) ureas | |
US3311613A (en) | Derivatives of glycyrrhetinic acid and process for the preparation thereof | |
US3332958A (en) | Bis-(amino alkoxy phenyl)sulfides, sulfoxides and sulfones | |
US3726893A (en) | 2-(p-phenylbenzyl)oxazolines | |
US3687936A (en) | 11-AMINOALIPHATIC-5:10-METHANODIBENZO {8 a:d{9 {0 {8 1:4{9 {0 CYCLOHEPTADIENES AND THE SALTS THEREOF | |
US3679686A (en) | N-(bicycloamino-alkanoyl)-anilines | |
US3296071A (en) | Reducing blood sugar with 3-alkyl-5-alkoxymethylisoxazole | |
DD148633A5 (en) | PROCESS FOR PREPARING HEXAHYDRO-1,4-OXAZEPINENE | |
US3708510A (en) | Amides of cholanic acid,cholenic acid,and choladienic acid |